Elena P. Mazunina

This study compares three TBEV vaccine candidates—mRNA-LNP, recombinant adenovirus, and YFV chimera—and finds the mRNA-LNP vaccine has higher immunogenicity and protective efficacy in mice.

This study develops a trivalent mRNA vaccine candidate for seasonal flu, showing higher immunogenicity and cross-specific humoral immune response compared to an inactivated split vaccine.

This study evaluates mRNA-LNP vaccines encoding SARS-CoV-2 structural proteins, finding that the S protein enhances immune responses to N protein, while M protein has low immunogenicity.

This paper develops an mRNA platform for delivering single-domain antibodies, achieving 100% protection against high doses of botulinum neurotoxin A in mice.